

January 2025

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. Hikma has an established and growing presence in Europe, having operated there since the 1990s. Through our high-quality manufacturing plants in Portugal, Italy and Germany, we supply generic injectable medicines to North America, Europe, and Middle East and North Africa (MENA).

## Local expertise, global strength

 **3** locations with **5** manufacturing plants

 **1,300+** skilled employees

 **2** R&D centres

 **7** commercial offices

## Manufacturing capabilities

With an installed capacity of over 500 million units, expansion is underway in both the EU and the US.

### Sintra, Portugal, the global hub for the Injectables business:

- Three segregated plants for the manufacturing of general formulation products, high containment products and Cephalosporins antibiotics
- Our capabilities cover different forms and technologies, including vials and ampoules, prefilled syringes, IV bags, emulsions/suspensions and oils
- The site services, the US, EU, UK and MENA markets

### Goslar, Germany:

- One plant
- Our capabilities include cytotoxic manufacturing of both liquid and lyophilised vials
- The site services the US, EU and MENA markets

### Pavia, Italy:

- One plant
- Our capabilities include liquid and lyophilised vials, and liquid ampoules
- The site services the EU and MENA markets

## R&D sites



Sintra, Portugal



Zagreb, Croatia

## Integrated CMO services

Our contract manufacturing integrated services for injectable products offer a range of capabilities, ensuring high-quality at every stage and supporting our partners needs from industrial process development all the way to commercial manufacturing.

## Commercial offices

We supply high-quality medicines to European hospitals and retail markets.

**BENELUX**

**Italy**


**France**

**Portugal**

**Germany and Austria**

**Spain**

**UK and Nordics**



## Therapy areas



Anti-infectives



Central Nervous System



Cardiovascular



Oncology



Musculoskeletal



Respiratory



Digestive and metabolic system



Anti-neoplastics and Hormonal therapy

### Company information

Chief Executive Officer:  
Riad Mishlawi

Chief Financial Officer:  
Khalid Nablsi

### Hikma Pharmaceuticals PLC

1 New Burlington Place London  
W1S2HR, UK

### Contacts

See [www.hikma.com](http://www.hikma.com) for contact forms